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Abstract: Many processes regulating immune responses are initiated by G-protein coupled 
receptors (GPCRs) and report biochemical changes in the microenvironment. Dendritic 
cells (DCs) are the most potent antigen-presenting cells and crucial for the regulation of 
innate and adaptive immune responses. The lipid mediator Prostaglandin E2 (PGE2) via 
four GPCR subtypes (EP1-4) critically regulates DC generation, maturation and migration. 
The role of PGE2 signaling in DC biology was unraveled by the characterization of EP 
receptor subtype expression in DC progenitor cells and DCs, the identification of the 
signaling pathways initiated by these GPCR subtypes and the classification of DC 
responses to PGE2 at different stages of differentiation. Here, we review the advances in 
PGE2 signaling in DCs and describe the efforts still to be made to understand the  
spatio-temporal fine-tuning of PGE2 responses by DCs. 
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Abbreviations: Gβ, Gγ, heterotrimeric guanine nucleotide-binding proteins; Gαs, stimulatory 
guanine nucleotide binding protein; Gαi, inhibitory guanine nucleotide binding protein; AC, adenylate 
cyclase; AMP, adenosine monophosphate; cAMP, cyclic 3,5-adenosine monophosphate; PKA, protein 
kinase A; GSK-3α, glycogen synthase kinase-3; PI3K, phosphatidyl-inositol 3 kinase; Akt, also known 
as Protein Kinase B; CREB, cAMP response element–binding protein; Tcf, T-cell factor; Lef, 
lymphoid enhance factor; ERK, extracellular signal-regulated kinase; EGR-1, early growth response 
protein 1; GRK, G-protein coupled receptor kinase. 
1. G-Protein-Coupled Receptor Signaling 
The ability of cells to communicate with and respond to their external environment is critical for 
their survival and function. G-protein-coupled receptors (GPCRs) constitute a large and diverse  
family of proteins, which are crucial intermediates in the transmission and translation of extracellular 
information into intracellular responses [1]. The GPCR signaling cascade starts by binding a ligand to 
its receptor, thereby activating downstream signaling pathways, which finally result in complex 
cellular responses. The signaling and trafficking properties of GPCRs are often highly malleable 
depending on the cellular context. Receptor-interacting proteins that are differentially expressed in 
distinct cell types can attribute such plasticity of GPCR function. In addition, the spatiotemporal  
fine-tuning of a cell’s response to extracellular signals also depends on the probability of interaction 
between the receptor and its interaction partners, and this is controlled by the organization and lateral 
mobility of the signaling components within the plasma membrane [2–7]. Mechanisms exist that can 
control receptor localization and mobility, such as compartmentalization caused by cytoskeletal 
contacts, lipid environment or protein-protein interactions. Unraveling the mechanisms controlling 
GPCR signaling may lead to novel therapeutic approaches for treating diseases since GPCRs are 
amenable drug targets. 
1.1. Immune Regulation by Dendritic Cells 
Immune diseases and cancer are caused by a derailed or ineffective immune system. Understanding 
the molecular mechanisms that shape an effective immune response is a fundamental question in 
biology and essential towards the development of novel therapeutics.  
Immune responses are orchestrated by a diverse group of functionally specialized, highly 
differentiated hematopoietic cell lineages. Dendritic cells (DCs) are the most effective antigen (Ag) 
presenting cells that play a central role in the induction of T-cell-mediated immunity [8]. In addition to 
activating the immune response, DCs are also decisive in creating tolerance. The pathway that is 
activated depends on the final balance between incoming signals [9]. In response to antigen uptake and 
exposure to inflammatory stimuli, DCs undergo a dramatic phenotypic conversion from a tissue 
resident, Ag-capturing cell to a highly migratory Ag-presenting cell, a process known as DC 
maturation. Activated DCs run an intricate migration track throughout the body involving the 
migration from peripheral tissues towards and their entry into the lymphatic vessels, as well as their 
final positioning in T-cell areas within the lymph nodes where they stimulate naïve T cells and initiate 
immune responses [8]. DCs are being exploited in the clinic for boosting immunological responses 
against various cancers by vaccination of cancer patients with ex vivo-generated autologous DC loaded 
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with tumor antigens. However, although immunological responses are observed in most studies, 
clinical responses are limited to a minority of patients. The success of DC-based immunotherapy in 
inducing cellular immunity against tumors is highly dependent on accurate delivery and trafficking of 
the Ag-loaded DC to T-cell-rich areas of secondary lymphoid tissues [10,11]. Therefore, in order to 
improve the clinical outcome, it is of the utmost importance to understand the molecular mechanisms 
that regulate the differentiation, maturation and migration of DC in order to optimize and steer the 
immune-regulatory capacities of ex vivo-generated DCs.  
While extensive research addresses the role of chemokines and cytokines in DC function [12], only 
recently the role of lipid mediators in DC differentiation and function has been highlighted, when their 
indispensable role in the DC lifecycle became clear [13–16]. DC differentiation from hematopoietic 
stem cells (HSCs) and DC function are sensitive to sources of lipid mediators, such as prostaglandins, 
and DCs express several receptors involved in prostaglandin signaling pathways [17]. Prostaglandin 
E2 (PGE2) is a key modulator of DC differentiation from their specific progenitor cells [18], DC 
maturation, migration and production of cytokines to influence T cell differentiation [19–22]. 
Depending on the site of encounter and the maturation stage, PGE2 acts both as an immunoactivator 
and as an immunosuppressor in DCs, exerting a stimulatory function for immature DCs in peripheral 
tissues [19], and an inhibitory function for mature DCs in the lymph nodes [23]. Finally, PGE2 
differentially regulates cytokine production by DCs as a response to the context and changes in the 
microenvironment [22,24,25]. 
1.2. PGE2 Signaling 
The lipid mediator PGE2 is a cyclooxygenase (COX) metabolite of arachidonic acid and  
exhibits the most versatile actions in a wide variety of tissues, modulating various pathological and 
physiological activities, such as cancer, fever, inflammation, atherosclerosis, blood pressure, stroke, 
and reproduction [26,27]. Arachidonic acid is modified by the constitutively active COX-1 and the 
inducible COX-2 producing prostaglandin H, which is further converted by three different PGE 
synthases, a cytosolic PGE synthases (cPGES) and two membrane bound PGE synthases (mPGES1 
and mPGES2). cPGES and mPGES2 are constitutive active, whereas mPGES1 is inducible [28]. 
Finally, PGE2 is degraded by 15-hydroxyprostaglandin dehydrogenase (15-PGDH), the hydroxyl 
group is oxidized into 15-keto metabolites which exhibit greatly reduced biological activities [29,30].  
PGE2 biological actions have been attributed to its interactions with specific GPCRs localized at the 
plasma membrane [17]. PGE2 is believed to act in an autocrine and a paracrine manner via a family  
of four cell surface or nuclear membrane GPCRs termed EP1-EP4, with distinctive signaling  
pathways [31]. EP1 is coupled to Gαq/p and activates phosphoinositide-phospholipase C (PLC), which 
ultimately leads to an increase in intracellular Ca2+ [32]. EP2 and EP4 are coupled to the stimulatory 
Gαs, which leads to an increase in intracellular adenosine-3',5'-cyclic monophosphate (cyclic adenosine 
monophosphate or cAMP) upon activation. Additionally EP4 has been described to be coupled to a 
Pertussis toxin-sensitive inhibitory G-protein, Gαi [33]. This will be discussed in more detail in the 
next paragraph. EP3 exists in three isoforms, all activating Gαi, which decrease cAMP production. 
Mouse studies suggest that the activation of these receptors induce multiple physiological functions: 
for example it mediates stress responses [34,35], it facilitates ovulation and fertilization [36], it 
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regulates duodenal secretion [37] and it induces bone formation [38]. The specificity and diversity of 
PGE2 effects can be explained by the local PGE2 concentration due to the balance between its  
COX2-regulated synthesis and 15-PGDH-driven degradation, along with the characteristic expression 
pattern of different EP receptors with distinctive signaling mechanisms.  
PGE2 stimulates a broad spectrum of responses throughout most immune cells as reviewed in [39]. 
For example, PGE2 selectively suppresses effector functions of macrophages and neutrophils and the 
Th1-, CTL-, and NK cell-mediated type 1 immunity at micromolar concentrations and stimulates Th1 
and Th17 at nanomolar concentrations [40]. In addition, PGE2 supports differentiation, maturation and 
migration of DCs but suppresses their ability to attract naive, memory, and effector T cells. PGE2 
regulates the immune response towards Th2 and Th17 immunity and enhances the local accumulation 
of regulatory T cells and myeloid-derived suppressor cells [41,42].  
Dependent on DC subtype and species (human or mouse), DCs were shown to express either  
EP2 and EP4 or all four EP receptors, however PGE2 exerts its effects only via EP2 and EP4  
(Figure 1) [19,21,26,43,44]. The distinguishing feature of the EP2 and EP4 receptors is that their 
signaling is predominantly transduced by Gαs, through which receptor activation is associated with an 
increase in adenylate cyclase activity and subsequently elevated intracellular cAMP levels [45,46]. 
However, EP4 ligation induces a weaker stimulation of intracellular cAMP when compared to the 
ligation of EP2 expressed at similar levels, although EP4 is known to have a higher affinity for  
PGE2 [47]. The production of cAMP and subsequently protein kinase A (PKA) leads to the 
phosphorylation of glycogen synthase kinase-3 (GSK-3) stimulating Tcf/Lef transcriptional activity. 
However, although EP4 is able to activate this signaling pathway, EP4 primarily induces Tcf/Lef 
transcriptional activity via a phosphatidyl-inositol 3 kinase (PI3K)-dependent pathway [48] through 
activation of Gαi [33,49]. In addition, EP2 and EP4 differentially regulate the PGE2-mediated 
phosphorylation of the cAMP response element–binding protein (CREB), central to the regulation of 
cAMP responsive gene expression: EP2 stimulates the PKA- and EP4 mainly the PI3K-dependent 
pathway [50]. In contrast to EP2, EP4 induces the functional expression of early growth response 
factor-1 (EGR-1) via the PI3K/MAPK signaling pathway [47], which can result in the expression of 
PGE2 synthase [51]. This can act as a positive feedback loop in which ligation of EP4 by PGE2 leads to 
an increase in PGE2 production via PGE2 synthase. Another distinguishing feature of EP4 is its  
ligand-induced desensitization and internalization [48,52], depending on elements present in the 
carboxyl terminus of EP4. The carboxyl terminus of EP4 also contains sites for potential 
phosphorylation by G-protein coupled receptor kinases (GRK) [53], and arrestin-2 binding promotes 
EP4 internalization [54]. However, so far mutation of multiple potential GRK phosphorylation sites 
did not alter agonist-induced internalization [55], suggesting a different or more complex arrestin-EP4 
binding mechanism [54]. EP2 has a much shorter C-tail than EP4, which could be a possible 
explanation for its desensitization- and internalization resistance and lack of arrestin-2 binding. Indeed, 
an arrestin mutant that binds and desensitizes regardless of phosphorylation status of the receptor did 
promote EP2 internalization and attenuate EP2 receptor signaling [54].  
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Figure 1. Signaling pathways activated by PGE2 stimulation of the human EP2 and EP4 
prostanoid receptors. Phosphorylation of GSK-3α via either PKA or PI3K signaling 
pathway inhibits the kinase activity of GSK-3α. Inhibition of GSK-3α stabilizes β-catenin 
that results in a decrease in its degradation and promotes β-catenin nuclear translocation 
and transcriptional activity of Tcf/Lef-regulated genes. Activation of either PKA or PI3K 
signaling pathway leads to phosphorylation of the transcription factor CREB regulating 
cAMP responsive gene expression. Activation of the PI3K/ERK pathway induces 
functional expression of EGR-1, known to regulate PGE2 synthase. In addition, PI3K 
signaling pathway inhibits the activity of PKA. 
 
1.3. PGE2 and Hematopoiesis 
PGE2 has a prominent role in controlling the number of hematopoietic stem cells (HSCs) from the 
bone marrow [56,57], but also HSC present in cord blood [58]. Although all four PGE2 receptors were 
expressed in HSC at protein as well as at mRNA level [59], in the hematopoietic system only EP4 
seems operative as recently shown [60]. In vitro exposure of HSCs to PGE2 leads to better homing, 
survival and proliferation. The exposure of HSCs has profound influences on the enhanced expression 
of the C-X-C chemokine receptor type 4 (CXCR4) and survivin while the activity of caspase-3 is 
down-regulated, both processes inhibit apoptosis [61]. The CXCR4 receptor enhances the migration to 
stromal cell-derived factor-1 (SDF-1) in vitro and homing to the bone marrow in vivo [59]. Treatment 
in vitro and in vivo of HSC with PGE2 results in an increase in stem cell numbers [57]. Dissecting the 
identity of the responding HSC showed that long term HSCs were unaffected by PGE2 and that the 
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increase in HSC number was due to an expansion of the short term HSCs [62]. The latter HSC has less 
renewal capacity. Presently it is unknown if the long term HSC lacks the receptors for PGE2 or 
whether other downstream processes are modified. PGE2 signaling raises the level of β-catenin that is 
part of the Wnt signaling pathway that drives hematopoiesis [63]. The link between PGE2 and Wnt was 
pinpointed at LGR5, a molecule expressed by (cancer) stem cells and a Wnt target. The level of 
expression of LGR5 was upregulated by PGE2 [64]. Recently, it was shown that the upregulation of  
β-catenin is modulated via EP4 only [60]. Furthermore, PGE2 appears to have a dual effect by 
stimulating the HSC but also the HSC supporting niche, again via the EP4 receptor [60]. 
After a massive expansion step, HSC differentiate into the eight different blood cell types. Most of 
these blood cells are insensitive to PGE2 since blocking of PGE2 production does not influence the 
differentiation of T cells, B cells and NK cells. In contrast, the number of monocytes increases and the 
number of DCs decreases after blocking PGE2 synthesis with indomethacin [18]. Optimal development 
of DCs is regulated by PGE2 via the EP1 and EP3 receptor. Triggering increases the receptor for Flt3, 
which is an important cytokine in DC development [60]. Thus, PGE2 has regulatory properties on 
several stages of development of the hematopoietic system, these modulating effects being mediated 
by different receptor expression patterns. 
1.4. PGE2 Responses in Dendritic Cells 
Various studies have demonstrated a multifaceted response of DCs to PGE2. In particular,  
it recently became clear that the timing and extent of DC exposure to this lipid determine different 
cellular outcomes. Ex vivo, DCs can be generated through differentiation of peripheral blood 
monocytes in the presence of interleukin-4 (IL-4) and granulocyte macrophage colony-stimulating 
factor (GM-CSF) [65,66]. These moDCs are a well-established system to study DCs and they are 
currently also exploited in several anti-tumor clinical trials [10,67]. Differentiation of inflammatory 
monocytes into DCs has been shown to also occur in vivo [68], thus making the moDCs a valid model 
cell system. 
The generation of DCs from peripheral blood monocytes has been shown to be inhibited in the 
presence of PGE2, either exogenously added or secreted by co-cultured mesenchymal stem cells [69]. 
More recently, Kalinski and colleagues demonstrated that a positive feedback loop between PGE2 and 
its synthesizing enzyme COX2 is able to redirect the differentiation of monocyte cultures towards 
stable myeloid-derived suppressor cells, which have opposing role in the immune system as compared 
to DCs [70]. In contrast to its inhibitory effects on monocytes, PGE2 exhibits an activating function on 
the immature moDCs. In fact, PGE2 is a key regulator of DC maturation, in particular responsible for 
the acquisition of a migratory phenotype. As a first step towards the transition from an adhesive  
to a highly migratory state, DCs dissolve specific integrin- and actin-rich adhesive structures called 
podosomes within minutes after PGE2 stimulation [20,71]. This fast response to PGE2 is mediated by 
elevation of cAMP intracellular levels, activation of the small GTPase RhoA and subsequent  
induction of actomyosin contraction ultimately leading to fast podosome dissolution [21]. Combined 
with proinflammatory cytokines, PGE2 specifically upregulates the surface expression levels of the 
chemokine receptor CCR7, which is responsible for the chemotactic responsiveness of DCs to lymph 
node-derived chemokines such as CCL19 and CCL21 [72]. Furthermore, prolonged incubation of DCs 
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with PGE2 induces expression of matrix metalloproteinase 9 (MMP-9), which together with CCR7 is 
responsible for the directional migration of DCs to draining lymph nodes [73,74]. It should be noted 
that to enable DC chemotaxis, PGE2 addition is absolutely required at early time points of maturation, 
as addition of PGE2 during terminal maturation stages is no longer effective [19]. 
Besides stimulating DC migration, PGE2 plays also a role in enhancing the T cell stimulatory 
capacity of DCs by inducing the upregulation of costimulatory receptors such as OX40L, CD70 and  
4-1BBL early during DC maturation that results in an increased capacity to induce proliferation of 
CD4+ and CD8+ T cells [75], despite the concomitant induction of several suppressive factors like 
thrombospondin-1 [76] and IDO [77], known to suppress T cell proliferation and survival promoting 
tolerance. In addition, DC function is influenced by the production of specific cytokines. PGE2 induces 
IL-10 production, a known inhibitor of DC maturation [78] and suppresses the production of IL-12, 
shifting the balance from a Th1 to a Th2 response [79,80]. A very recent study by Woodward and 
colleagues demonstrated that PGE2 can differentially regulate DC production of cytokines depending 
on the EP receptor that is stimulated [81]. For example, low concentrations (up to 10 nM) of  
PGE2 appear to stimulate the Th17 response supporting IL-23 release via EP4 [82], whereas at 
concentrations higher than 50 nM PGE2 inhibits IL-23 production in an EP2 dependent manner [81]. 
These novel findings indicate that subtle changes in PGE2 concentration in the extracellular 
microenvironment can specifically activate one particular receptor thus differentially modulating 
cellular responses.  
Interestingly, the effects of PGE2 on naturally occurring DC subsets seem to be quite diverse. For 
example, signaling of PGE2 through EP4 was found to facilitate the initiation of skin immune 
responses by enhancing maturation and migration of Langerhans cells [43]. In contrast, on human 
plasmacytoid DCs (pDCs) PGE2 has been shown to potently inhibit secretion of IFN-alpha by pDCs 
upon stimulation with Toll-like receptor ligands, with subsequent decreased secretion of Th1 cytokines 
by co-cultured T cells [83]. PGE2 inhibits IFN-alpha secretion and Th1 costimulation by human pDCs 
via EP2 and EP4 engagement [84]. PGE2 can therefore be considered as a negative regulator on human 
pDCs [85]. Considering the large variety of properties and functions of the various DC subsets, might 
lead to multiple cellular responses. This once again highlights the complexity and multifaceted action 
of PGE2 signaling in DCs. 
2. Outlook 
PGE2 acts both as an immunosuppressor and an immunoactivator throughout the lifecycle of DCs 
(Figure 2). Therefore, knowledge on the complexity of PGE2 signaling is necessary in order to predict, 
control and intervene in the PGE2 response in experimental and possibly clinical settings. The different 
cellular effects mediated by PGE2 in DCs marginally depend on the expression pattern of the EP 
receptors. Although differentiation of DCs seems regulated via EP1 and EP3, the function of DCs 
during their lifecycle is always regulated via EP2 and EP4. Therefore, the expression levels of EP2 and 
EP4, their different affinity for PGE2 and the extent of activation of the different signaling pathways 
downstream of EP2 and EP4 will enable a DC to tune cellular outputs in response to PGE2. The extent 
of EP2 and EP4 activity is critically dependent on the probability of interaction between the receptor 
and receptor-interacting proteins, like Gαs, Gαi and arrestin, and subjected to precise regulation of 
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localization in time and space. Furthermore, cross talk of the EP2 and EP4 signaling pathways might 
occur as well as cross talk by different receptors, influencing the availability of receptor interacting 
partners or downstream signaling proteins. To fully understand PGE2 regulated processes in DCs, all 
individual molecular interactions should be followed in space and time, which would allow us to build 
a dynamic and quantitative signaling network connectivity-map for prediction of the DC response  
to PGE2 based on parameters like for example, receptor numbers, affinities etc. With the rapid 
development and improvement of high-resolution bioimaging techniques suited for the investigation of 
fast signal transduction processes at the molecular level [86], we expect to be able to simultaneously 
investigate multiple molecular interactions involved in the PGE2 receptor signal cascade, which might 
represent a paradigm for other GPCR signaling pathways.  
Figure 2. The multifaceted roles of PGE2 during the lifecycle of dendritic cells. 
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